EXOZYMES INC.(EXOZ)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
EXOZ Stock Analysis & AI Quality Score
AI stock analysis and institutional research for EXOZYMES INC. (EXOZ), a Healthcare sector company. EXOZ is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), EXOZYMES INC. reports net income of $-2.4M, free cash flow of $-1.6M. Top institutional holders of EXOZ by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. EXOZ trades on the Nasdaq exchange and files with the SEC under CIK 2010788. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EXOZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXOZYMES INC. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.4M
Free Cash Flow
Q1 2026
$-1.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-56.3% YoYOperating Income
-63.8% YoYEPS (Diluted)
-22.5% YoYTotal Assets
-54.2% YoYOp. Cash Flow
+23.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | $70.1K | — |
| Net Income | $-9.2M -56.3% | $-5.9M -187.5% | $-2.0M | — |
| Operating Income | $-9.7M -63.8% | $-5.9M -230.3% | $-1.8M | — |
| EPS (Diluted) | $-1.09 -22.5% | $-0.89 -169.7% | $-0.33 | — |
| Total Assets | $6.0M -54.2% | $13.0M +266.3% | $3.6M | — |
| Operating Cash Flow | $-6.5M +23.6% | $-8.5M -620.3% | $-1.2M | — |
AI Insight: EXOZ Ratio Trends
EXOZ shows severe and accelerating negative returns across all profitability metrics through Q3 2025, with ROE deteriorating from −70.5% to −170.2% over four quarters.
• ROE collapsed from −70.5% in Q4 2024 to −170.2% in Q3 2025, signaling deepening losses relative to shareholder equity.
• ROA worsened from −56.3% in Q4 2024 to −97.6% in Q2 2025, indicating deteriorating asset utilization and mounting operating losses.
• ROIC declined from −76.1% in Q4 2024 to −87.8% in Q1 2025, showing capital destruction across the measured period.
⚠ No profitability metrics reported for Q4 2025 or Q1 2026 TTM; financial condition and turnaround progress remain opaque.
⚠ Consistent negative ROIC, ROE, and ROA across all quarters suggest structural unprofitability rather than cyclical weakness.
Get alerted when EXOZ's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for EXOZYMES INC. including:
Top Institutional Holders of EXOZ
VANGUARD CAPITAL MANAGEMENT LLC
$166.4K22,190 shGEODE CAPITAL MANAGEMENT, LLC
$164.2K21,891 shVANGUARD FIDUCIARY TRUST CO
$70.7K9,426 shBlackRock, Inc.
$51.0K6,797 shTower Research Capital LLC (TRC)
$9.9K1,317 shMORGAN STANLEY
$9.4K1,250 shUBS Group AG
$180.0024 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $166.4K | 22,190 |
| GEODE CAPITAL MANAGEMENT, LLC | $164.2K | 21,891 |
| VANGUARD FIDUCIARY TRUST CO | $70.7K | 9,426 |
| BlackRock, Inc. | $51.0K | 6,797 |
| Tower Research Capital LLC (TRC) | $9.9K | 1,317 |
| MORGAN STANLEY | $9.4K | 1,250 |
| UBS Group AG | $180.00 | 24 |
More Healthcare Companies
View all Healthcare →Put EXOZ on your watchlist
Track score changes the day EXOZYMES INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EXOZ a good stock to buy?
13F Pro's AI-powered analysis of EXOZYMES INC. (EXOZ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EXOZ are available on the EXOZ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own EXOZ?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EXOZ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of EXOZYMES INC.'s investment landscape.